Accelerating cell therapy discovery & development with non-viral gene engineering
Sponsor
Gene engineering of immune cells has become a powerful tool for creating cellular therapies. Currently, this critical step is primarily performed using virus-based gene delivery systems (e.g. lentivirus). However, virus-based engineering methods are plagued with long lead times, inconsistent batches, low cargo capacity, and high costs.
Recently, advances in non-viral gene engineering methods, including transposon-based systems, have provided developers with an alternative gene engineering method that addresses these limitations. Utilizing a “cut-and paste” method of gene delivery, transposon-based systems are capable of stable genomic integration. TcBuster™ is one such transposon-based system and in this webinar we will present data demonstrating both T cell and NK cell gene editing using the technology.
How the mechanism of transposon-based gene engineering systems address the current challenges virus-based systems face What is TcBuster and how does it work How TcBuster compares to other delivery platforms for primary immune cells How TcBuster can be adopted into your pipeline as a research use or GMP compliant system
SPEAKERS
You might also like
Achieving cost effective, scalable high-titer AAV production
Hit the lentiviral characterization jackpot with accurate RNA detection
Mastering allogeneic NK cell therapies: flexibility, robustness, and speed to clinic
Biological & operational considerations for iPSC-derived cell production
